Skip to content

Ketamine: all studies

Page 423 of 449: studies 4,221 to 4,230 of 4,490, newest first. Back to the ketamine overview

Research

Alteration of Depressive-like Behaviors by Psilocybe cubensis Alkaloid Extract in Mice: the Role of Glutamate Pathway

SHILAP Revista de lepidopterología March 1, 2018 Elaheh Mahmoudi, Mehrdad Faizi, Reza Hajiaghaee et al. 14 citations

Background and objectives: Considering the increasing prevalence of depression, many studies are launched to investigate new antidepressant treatments. The present research has shown how psilocybin as an active compound of Psilocybe cubensis (Earle) Singer extract (PCE) can change the parameters related to depression and anxiety in animal models. Both serotonin (5-hydroxytryptamine: 5-HT) and...

Skin picking disorder comorbid with ADHD successfully treated with methylphenidate

Revista Brasileira de Psiquiatria February 24, 2018 Camila Bernardes, P. Mattos, B. P. Nazar

Rev Bras Psiquiatr. 2018;40:110 Brazilian Journal of Psychiatry 00000000-0002-7316-1185 | doi:10.1590/1516-4446-2017-2380 Singh et al. reported that two or three weekly 40 min i.v. infusions of ketamine (0.5 mg/kg) are safe and effective for maintaining an acute response to ketamine during one month of treatment for resistant depression (TRD). We present herein the results of an open label...

Glutamatergic Modulators in Depression

Harvard Review of Psychiatry February 21, 2018 Ioline D. Henter, Rafael Teixeira de Sousa, Carlos A. Zarate 94 citations

LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions...

DOI: 10.1097/hrp.0000000000000183 (opens in new tab) Glutamatergic Dextromethorphan Pharmacology Nmda receptor +5

Loss of consciousness is related to hyper-correlated gamma-band activity in anesthetized macaques and sleeping humans.

Neuroimage February 15, 2018 Michał Bola, Adam B. Barrett, Andrea Pigorini et al.

Loss of consciousness can result from a wide range of causes, including natural sleep and pharmacologically induced anesthesia. Important insights might thus come from identifying neuronal mechanisms of loss and re-emergence of consciousness independent of a specific manipulation. Therefore, to seek neuronal signatures of loss of consciousness common to sleep and anesthesia we analyzed...

Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder

Journal of Addiction Medicine February 4, 2018 Matteo Caloro, Giuseppa Calabrò, Eleonora de Pisa et al. 9 citations

: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. CASE REPORT: We describe a case of a 32-year-old man who started at...

Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Psychopharmacology February 2018 Elena Martín-González, Ángeles Prados-Pardo, Santiago Mora et al.

Clinical studies have shown that some psychoactive recreational drugs have therapeutic applications in anxiety, depression, and schizophrenia. However, to date, there are few studies on the therapeutic potential efficacy of recreational drugs in compulsive neuropsychiatric disorders. We explored the therapeutic potential of different psychoactive and psychedelic drugs in a preclinical model of...

DOI: 10.1007/s00213-017-4819-y (opens in new tab) Full text (opens in new tab) Compulsivity Psychedelic drugs Psychoactive drugs Schedule-induced polydipsia

Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues.

Drug Testing and Analysis February 1, 2018 Tristan Colestock, Jason Wallach, Matt Mansi et al. 14 citations

New psychoactive substances (NPS) are commonly referred to as 'research chemicals', 'designer drugs' or 'legal highs'. One NPS class is represented by dissociative anesthetics, which include analogues of the arylcyclohexylamine phencyclidine (PCP), ketamine and diphenidine. A recent addition to the NPS market was 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo), a morpholine analogue of...

DOI: 10.1002/dta.2213 (opens in new tab) Full text (opens in new tab) Nmda receptor Pcp Arylcyclohexylmorpholines Dissociative anesthetics +1

Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects

The International Journal of Neuropsychopharmacology January 13, 2018 J. Donello, P. Banerjee, Yong-Xin Li et al.

Abstract Background Modulation of glutamatergic synaptic transmission by N-methyl-D-aspartate receptors can produce rapid and sustained antidepressant effects. Rapastinel (GLYX-13), initially described as a N-methyl-D-aspartate receptor partial glycine site agonist, exhibits rapid antidepressant effect in rodents without the accompanying dissociative effects of N-methyl-D-aspartate receptor...

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers.

Journal of Visualized Experiments January 13, 2018 Andria Pelentritou, Levin Kuhlmann, John Cormack et al.

Anesthesia arguably provides one of the only systematic ways to study the neural correlates of global consciousness/unconsciousness. However to date most neuroimaging or neurophysiological investigations in humans have been confined to the study of γ-Amino-Butyric-Acid-(GABA)-receptor-agonist-based anesthetics, while the effects of dissociative...

Music festival attendees' illicit drug use, knowledge and practices regarding drug content and purity: a cross-sectional survey.

Harm Reduction Journal January 5, 2018 Niamh Day, Joshua Criss, Benjamin J Griffiths et al.

Drug checking is a harm reduction strategy which allows users to check the content and purity of illicit drugs. Although drug checking has been trialled internationally, with demonstrated value as a harm reduction and health promotion strategy, the use of such services in Australia remains a contentious issue. This study aimed to investigate the proportion and patterns of illicit drug use among...